Left atrial appendage closure when anticoagulation is unsuitable

Atrial fibrillation remains the most common sustained cardiac arrhythmia encountered in Australian clinics, and it carries a well-recognised risk of thromboembolic stroke. For decades, oral anticoagulation with warfarin or direct-acting inhibitors has been the cornerstone of stroke prevention, yet a meaningful proportion of patients cannot tolerate these agents because of bleeding, falls, intracranial pathology or occupational risk. Left atrial appendage closure offers a mechanical alternative that has matured from a niche intervention into a routine part of structural heart practice.

The procedure has gained traction across tertiary centres in Melbourne, Sydney and Brisbane as device technology improves and reimbursement arrangements evolve. Clinicians involved in electrophysiology and structural cardiology increasingly discuss appendage occlusion as part of a shared decision-making conversation, particularly for older patients with frailty, recurrent gastrointestinal bleeding or a history of intracerebral haemorrhage. Understanding the evidence, patient selection criteria and procedural nuances is essential for any practitioner caring for people living with atrial fibrillation in Australia.

The stroke paradox in atrial fibrillation management

Stroke prevention in atrial fibrillation has always balanced ischaemic risk against haemorrhagic harm. Risk stratification tools such as CHA₂DS₂-VASc are embedded in Australian guidelines and routinely influence prescribing decisions, with thresholds for anticoagulation generally drawn at scores of two or more in men and three or more in women. HAS-BLED scoring, although imperfect, helps to flag patients who may experience major bleeding events while on therapy.

The paradox is that the very patients at highest ischaemic risk are often those most vulnerable to anticoagulant complications. Elderly patients with a history of falls, those with recurrent gastrointestinal angiodysplasia bleeding, and individuals who have survived an intracerebral haemorrhage present a recurring dilemma in cardiology outpatient clinics. In these scenarios, clinicians look for strategies that decouple stroke prevention from chronic exposure to antithrombotic drugs. Procedural left atrial appendage closure has emerged as the most extensively studied mechanical answer to that dilemma.

Why the appendage matters as a thrombus source

The left atrial appendage is a trabeculated pouch that lies adjacent to the mitral annulus and has long been identified as the dominant site of thrombus formation in non-valvular atrial fibrillation. Autopsy and transoesophageal echocardiography studies suggest that more than ninety percent of left atrial thrombi in this setting originate within the appendage, a finding that underpins the rationale for mechanical exclusion.

Anatomical variation matters. The appendage can have one, two or more lobes, with considerable variability in ostial diameter and depth between individuals. Cardiac CT performed prior to the procedure helps to size the device and anticipate procedural challenges, particularly in patients with shallow or wide-necked appendages. Australian imaging services have widely adopted pre-procedural CT angiography, and most high-volume centres use either a Watchman, Watchman FLX or Amplatzer Amulet device selected according to anatomical fit.

Defining who cannot take anticoagulants

Strict contraindications to oral anticoagulation are relatively uncommon, but relative contraindications are frequent. Intracranial haemorrhage, recurrent falls in the context of cognitive impairment, end-stage renal disease with bleeding tendency, and recurrent gastrointestinal bleeding from angiodysplasia or peptic ulceration all feature in real-world referral letters. Patients who require dual antiplatelet therapy after recent coronary stenting, and those undergoing cancer treatment with bleeding complications, also populate waiting lists for structural intervention.

Formal consensus guidance groups candidates into categories based on perceived reversibility of the bleeding risk. Some patients are temporarily unsuitable while others have a permanent contraindication. Distinguishing between these groups shapes the consent process and helps define the duration of post-implant antithrombotic therapy. Australian Heart Rhythm Society position statements mirror international consensus and emphasise multidisciplinary review before device implantation, with input from neurology, haematology and geriatrics where appropriate.

Devices, implants and procedural workflow

Two device families dominate contemporary Australian practice. The Watchman FLX is a nitinol frame covered by a polyester fabric that anchors in the appendage ostium and is approved by the Therapeutic Goods Administration for left atrial appendage closure. The Amplatzer Amulet is a nitinol mesh device with a lobe and disc configuration that seals the appendage from the left atrial side, also TGA approved and widely used. Operator preference, appendage anatomy and local procurement contracts often determine which platform is selected for an individual patient.

Procedural workflow typically involves transoesophageal echocardiography or intracardiac echocardiography guidance, femoral venous access, transseptal puncture and device deployment under fluoroscopy. Patients are usually observed overnight, and most Australian centres have transitioned to same-day or next-day discharge for uncomplicated cases. Antithrombotic regimens after implantation vary between short-term dual antiplatelet therapy, direct-acting anticoagulant for forty-five days followed by aspirin, or aspirin alone depending on bleeding history and device choice. Procedural complication rates at experienced centres in Australia mirror international registries, with serious pericardial effusion and device embolisation both under one percent in contemporary series. For clinicians comparing structural interventions more broadly, leadless pacemaker outcomes provide a useful adjacent perspective on device maturation in Australian practice.

Evidence base and real-world outcomes

The PROTECT-AF and PREVAIL randomised trials established non-inferiority of left atrial appendage closure to warfarin for stroke prevention in non-valvular atrial fibrillation, with subsequent analyses suggesting superiority in some bleeding-sensitive endpoints. The EWOLUTION registry and ASAP studies extended these findings to patients with absolute contraindications to anticoagulation, demonstrating meaningful reductions in expected stroke rates.

More recently, the Amplatzer Amulet IDE trial provided head-to-head data against Watchman, showing comparable stroke prevention with low device-related complications. Australian sites have contributed to several of these multinational registries, and local audit data from centres such as Royal Melbourne Hospital and St Vincent's Sydney align with international benchmarks. Long-term data out to five and ten years continue to accumulate, with consistent signals that procedural left atrial appendage closure offers durable protection in appropriately selected patients.

Australian practice, funding and access pathways

Funding remains the single biggest determinant of access. The Medical Services Advisory Committee has assessed left atrial appendage closure on multiple occasions, and Medicare Benefits Schedule rebates are currently available for procedures performed in approved centres using TGA-listed devices. Private health insurers also provide cover, although out-of-pocket costs vary between funds and individual specialists. Public hospital access is concentrated in metropolitan tertiary centres, with patients in regional and remote areas of Queensland, Western Australia and the Northern Territory often travelling significant distances for assessment and implantation.

Workforce capacity is another consideration. Operators require training in transseptal puncture, echocardiographic guidance and device deployment, and Australian Heart Rhythm Society accreditation pathways help to standardise credentialing. Wait lists for structural intervention in public hospitals can extend beyond six months, prompting some referring physicians to direct suitable patients into private practice pathways. Indigenous Australians carry a disproportionate burden of atrial fibrillation and stroke, and culturally safe models of care are increasingly recognised as essential to equitable access, particularly for those living in remote communities who may otherwise miss out on procedural options altogether.

Gaps in evidence and future directions

Several questions remain. The optimal post-implant antithrombotic regimen is still being defined, with ongoing trials evaluating abbreviated drug therapy or even single antiplatelet agents after device endothelialisation. Comparative effectiveness research against direct-acting anticoagulants in patients without bleeding history is limited, although registries continue to mature. The role of left atrial appendage closure in patients with hypertrophic cardiomyopathy, cardiac amyloidosis or chronic kidney disease requires further study, as these populations are often excluded from pivotal trials yet face high stroke risk.

Device technology continues to evolve. Next-generation occlusion platforms aim to reduce periprocedural complications, simplify deployment and accommodate a wider range of appendage morphologies. Combined procedures pairing left atrial appendage closure with catheter ablation for atrial fibrillation are under investigation, with early Australian experience suggesting feasibility in carefully selected patients. As evidence accumulates, procedural thresholds for intervention are likely to shift, and ongoing registry participation by Australian centres will help to define where mechanical stroke prevention sits alongside pharmacological therapy in the years ahead.

For clinicians seeking the latest peer-reviewed analyses, themed collections and original research on this and related arrhythmia topics, the journal articles archive offers open-access material relevant to daily practice. Researchers, reviewers and prospective authors with enquiries about manuscript submission, special issue proposals or educational contributions are warmly encouraged to reach out through the editorial team and help shape the conversation around stroke prevention in atrial fibrillation.